Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05376553
Recruitment Status : Not yet recruiting
First Posted : May 17, 2022
Last Update Posted : June 10, 2022
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Krzysztof Misiukiewicz, Icahn School of Medicine at Mount Sinai

Brief Summary:
The purpose of this research study is to determine the safety and tolerability of two dosing schedules of cemiplimab given in combination with cisplatin and docetaxel induction chemotherapy (TPI) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Cemiplimab is FDA approved for treatment of basal cell and squamous cell carcinoma of the skin as well as non-small cell lung cancer but not for squamous cell carcinoma of head and neck.

Condition or disease Intervention/treatment Phase
Locally Advanced Head and Neck Squamous Cell Carcinoma Drug: Cemiplimab Drug: Cisplatin Drug: Docetaxel Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Estimated Study Start Date : June 9, 2022
Estimated Primary Completion Date : May 2025
Estimated Study Completion Date : May 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort A
  • 3 cycles of Cemiplimab-TP induction chemotherapy will be delivered in cohort A.
  • Cemiplimab-TP chemotherapy will be given every 21 days starting on days 1, 22 and 43, etc. (+ 2 days) with TP given on days 1, 22, and 43 (+/- 2 days) and Cemiplimab given on days 14, 35, 56 (+/- 2 days).
  • Patients in cohort A will get 3 doses of Cemiplimab during induction therapy.
Drug: Cemiplimab
350mg intravenous infusion over 30 minutes

Drug: Cisplatin

100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline

Schedule: Day 1, every 21 days (+ 2 days)


Drug: Docetaxel

75 mg/2 intravenous infusion over 60 minutes, mixed as described in

Schedule: Day 1, every 21days (+ 2 days)


Experimental: Cohort B
  • In cohort B first dose of Cemiplimab will be given 7 days prior to TP followed by TP given on days 1,22,43 (+/- 2 days) and Cemiplimab given on days 14, 35, 56 (+/- 2 days).
  • Patient in cohort B will get 4 doses of Cemiplimab during induction therapy.
Drug: Cemiplimab
350mg intravenous infusion over 30 minutes

Drug: Cisplatin

100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline

Schedule: Day 1, every 21 days (+ 2 days)


Drug: Docetaxel

75 mg/2 intravenous infusion over 60 minutes, mixed as described in

Schedule: Day 1, every 21days (+ 2 days)





Primary Outcome Measures :
  1. Dose-limiting toxicity (DLT) [ Time Frame: During first cycle of cemiplimab (day 14) ]
    The dose-limiting toxicity (DLT) will be the basis for safety and toxicity of Cemiplimab -TP that will be measured and reported only during the first cycle of Cemiplimab -TP for the first 6 study objects in each cohort A and B since the majority of the DLT occurs after the first treatment cycle in multiple phase I oncology clinical trials. DLTs must be related to a study drug, cemiplimab. Known and expected chemotherapy (TP, standard of care) adverse events not related to cemiplimab will not be defined as DLTs.

  2. Dose-limiting toxicity (DLT) [ Time Frame: After 3 weeks of cemiplimab ]
    The dose-limiting toxicity (DLT) will be the basis for safety and toxicity of Cemiplimab -TP that will be measured and reported only during the first cycle of Cemiplimab -TP for the first 6 study objects in each cohort A and B since the majority of the DLT occurs after the first treatment cycle in multiple phase I oncology clinical trials. DLTs must be related to a study drug, cemiplimab. Known and expected chemotherapy (TP, standard of care) adverse events not related to cemiplimab will not be defined as DLTs.


Secondary Outcome Measures :
  1. Adverse events during induction therapy [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    Number of adverse events according to NCI CTCAE v4.0

  2. Blood Pressure [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
  3. Heart Rate [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
  4. Temperature [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
  5. Complete White Count (CBC) [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
  6. Sodium [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    A sodium blood test measures the amount of sodium in the blood. Sodium is a type of electrolyte. Electrolytes are electrically charged minerals that help maintain fluid levels and the balance of chemicals in the body called acids and bases. Sodium also helps the nerves and muscles work properly.

  7. Potassium [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    A potassium blood test measures the amount of potassium in the blood. Potassium is a type of electrolyte. Electrolytes are electrically charged minerals in the body that help control muscle and nerve activity, maintain fluid levels, and perform other important functions. The body needs potassium to help the heart and muscles work properly.

  8. Magnesium [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    A magnesium blood test measures the amount of magnesium in the blood. Magnesium is a type of electrolyte. Electrolytes are electrically charged minerals that are responsible for many important functions and processes in the body.

  9. Bicarbonate (CO2) [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    test to measures the amount of carbon dioxide in the liquid part of your blood, called the serum. The CO2 test is most often done as part of an electrolyte or basic metabolic panel. Changes in the CO2 level may suggest that the body is losing or retaining fluid.

  10. Phosphate [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    A phosphate in blood test measures the amount of phosphate in the blood. Phosphate is an electrically charged particle that contains the mineral phosphorus. Phosphorus works together with the mineral calcium to build strong bones and teeth.

  11. Calcium [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    The calcium blood test measures the level of calcium in the blood.

  12. Blood Urea Nitrogen (BUN) [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    Urea nitrogen is what forms when protein breaks down. This test measures the amount of urea nitrogen in the blood.

  13. Uric Acid [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    Uric acid is a chemical created when the body breaks down substances called purines. Most uric acid dissolves in blood and travels to the kidneys. From there, it passes out in urine. This test checks to see how much uric acid is in the blood.

  14. Glucose [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    Measures the glucose levels in your blood.

  15. Lactate Dehydrogenase (LDH) [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    This test measures the level of lactate dehydrogenase (LDH), also known as lactic acid dehydrogenase, in the blood or sometimes in other body fluids. If the LDH blood or fluid levels are high, it may mean certain tissues in the body have been damaged by disease or injury.

  16. SGOT (AST) [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    Aspartate aminotransferase (AST) blood test measures the level of the enzyme AST in the blood.

  17. SGPT (ALT) [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    The alanine transaminase (ALT) blood test measures the level of the enzyme ALT in the blood. ALT is an enzyme found in a high level in the liver. An enzyme is a protein that causes a specific chemical change in the body.

  18. Alkaline phosphatase (ALP) [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]

    Alkaline phosphatase (ALP) is a protein found in all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts, and bone.

    A blood test can be done to measure the level of ALP.


  19. Direct bilirubin [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    The bilirubin blood test measures the level of bilirubin in the blood. Bilirubin is a yellowish pigment found in bile, a fluid made by the liver.

  20. Total bilirubin [ Time Frame: At the end of Cycle 3 (each cycle is 21 days) ]
    The bilirubin blood test measures the level of bilirubin in the blood. Bilirubin is a yellowish pigment found in bile, a fluid made by the liver.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with stage III or IV, previously untreated, non-metastatic, locally advanced HNSCC (patients may have had previous surgery, but not chemotherapy or radiotherapy).

    a) Patients with oral cancer, HPV negative oropharyngeal cancer, high risk HPV+ oropharyngeal HNSCC confirmed by PCR. Patients with unknown primary, supraglottic, nasopharyngeal, and hypopharyngeal SCC will be allowed. High risk HPV defined as one of the following: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82.

  • A pretreatment biopsy of the primary site sufficient for immune studies is required.
  • Age >/= 18 years
  • ECOG PS 0-1
  • Hemoglobin > 8.0 g/dl, absolute neutrophil count > 1,500/mm3, platelet count > 100,000/mm3
  • Predicted life expectancy >/= 12 weeks
  • Total bilirubin <2.5 x Upper limit of normal (ULN); AST (SGOT) < 2.5 x ULN; ALT (SGPT) < 2.5 x ULN; serum creatinine </= 1.5 x ULN (Gilbert's disease allowed with elevated bilirubin)
  • Patients must be accessible for repeat dosing and follow-up
  • Patients - both males and females - with reproductive potential must agree to practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test at baseline and on Day 1
  • Patients must provide verbal and written informed consent to participate in the study.
  • A biopsy of the primary tumor or lymph node must be available for testing and immune evaluation

Exclusion Criteria:

  • Locally advanced EBV positive nasopharyngeal cancer, malignancies other than SCC head and neck cancer except surgically treated malignancies that are not active (e.g. surgically treated thyroid cancer, prostate cancer, breast cancer etc.) for 3 years or more and no evidence of active recurrence.
  • History of pneumonitis
  • History of prior immunotherapy
  • History of receiving PI3K inhibitors.
  • Patients at 1.5mg or more a day of dexamethasone (or equivalent).
  • History of significant cardiac disease unless the disease is well-controlled
  • Grade 2 peripheral neuropathy
  • No excessive alcohol consumption will be allowed
  • Serious comorbid illness, and involuntary weight loss of more than 20% of body weight in the 3 months preceding study entry
  • History of cerebrovascular accident (CVA) within 12 months prior to registration or that is not stable
  • History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent.
  • Pregnant or breast-feeding females.
  • GI abnormalities including inability to take oral medication, requirement for IV alimentation, active peptic ulcer, or prior surgical procedures affecting absorption
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug
  • Any type of active seizure disorder
  • Patients with history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
  • Use of strong or moderate CYP3A4 or CYP1A2 inhibitors/inducers, with the exception of low- dose steroids, within 14 days prior to Day 1 dosing
  • Symptomatic brain metastases that are not stable, require steroids, or that have required radiation within the last 28 days
  • Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study
  • History of Hepatitis c or HIV infection, autoimmune disease (except vitiligo and Hashimoto's thyroiditis), or major organ transplant
  • Any irradiation or chemotherapy in the past and no major surgical procedure in the last 4 weeks
  • Any other concomitant anticancer therapies
  • Patients will be excluded if they received any prior chemotherapy, radiotherapy, or treatment with biologic response modifiers (except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix)
  • History of colitis or chronic diarrheal illness
  • History of, or active, co-morbid medical condition, which in the opinion of the investigator, would raise significant risk to the patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05376553


Contacts
Layout table for location contacts
Contact: Krzysztof Misiukiewicz, MD 212-659-5609 krzysztof.misiukiewicz@mssm.edu
Contact: Li Zichen, (212) 824-2385 li.zichen@mssm.edu

Locations
Layout table for location information
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Contact: Krzysztof Misiukiewicz, MD    212-659-5609    krzysztof.misiukiewicz@mssm.edu   
Sponsors and Collaborators
Krzysztof Misiukiewicz
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Krzysztof Misiukiewicz, MD Icahn School of Medicine at Mount Sinai
Layout table for additonal information
Responsible Party: Krzysztof Misiukiewicz, Associate Professor, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT05376553    
Other Study ID Numbers: STUDY-21-01683
First Posted: May 17, 2022    Key Record Dates
Last Update Posted: June 10, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All of the individual participant data collected during the trial, after deidentification.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: Immediately following publication. No end date.
Access Criteria:

Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose.

To achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Docetaxel
Cemiplimab
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological